Description
Description
Estimated according to the population size and structure, there are about 330 million hypertensive patients in China, which means that one in every three adults suffers from hypertension. Chinese hypertensive patients in China account for about one-third of the global total. The incidence of hypertension in China rose from 5.1% in 1959 to 37.2% in 2017 by 32.1%. With so many hypertensive patients, China’s antihypertensive drug market is growing steadily.
There are various antihypertensive drugs in China, which leads to fierce competition. As first-line antihypertensive drugs in China, β-blockers represented by Metoprolol, Bisoprolol, Perindopril and benazepril have a stable market share. Metoprolol is a selective β1 receptor blocker that treats cardiovascular diseases, especially hypertension, angina and tachycardia. The Metoprolol Tartrate preparations approved to be marketed in China include tablets, capsules, sustained-release tablets, controlled-release tablets and injections. AstraZeneca’s proprietary drug is sold in the trade name of Betaloc. In addition, generic Metoprolol produced by over 10 manufacturers are also sold in China. According to CRI’s market research, the market size of Metoprolol in China was about CNY 492 million in 2017, of which AstraZeneca accounted for more than 90%. The top Chinese companies included Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., Shanghai Sine Promod Pharmaceutical Co., Ltd. and Zhuhai Tongyuan Pharmaceutical Co., Ltd.
As the number of hypertensive patients is growing with the rapidly aging population, and generic β-blockers are popularized, it is expected that Metoprolol will still have some growth potential in China.
Topics Covered:
– Situation of hypertension in China
– Sales of Metoprolol in China
– Major Metoprolol manufacturers in China
– Competition on China’s Metoprolol market
– Driving forces and opportunities for China’s Metoprolol market
– Forecasts on China’s Metoprolol market from 2018 to 2022
Table of Contents
Table of Contents
1 Relevant Concepts of Metoprolol
1.1 Indications for Metoprolol
1.2 Development of Metoprolol in China
1.3 Patents and Government Approval on Metoprolol in China
2 Sales of Metoprolol in China, 2013-2017
2.1 Sales Value of Metoprolol
2.2 Sales Volume of Metoprolol
2.3 Sales of Metoprolol by Dosage Form in China, 2013-2017
3 Analysis on Major Metoprolol Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Metoprolol Manufacturers
3.2 AstraZeneca
3.3 Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd.
3.4 Shanghai Sine Promod Pharmaceutical Co., Ltd.
3.5 Zhuhai Tongyuan Pharmaceutical Co., Ltd.
3.6 Changzhou Siyao Pharmaceuticals Co., Ltd.
4 Prices of Metoprolol in China, 2017-2018
4.1 AstraZeneca (Betaloc)
4.2 Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (Lijunning)
4.3 Shanghai Sine Promod Pharmaceutical Co., Ltd.
4.4 Zhuhai Tongyuan Pharmaceutical Co., Ltd.
4.5 Changzhou Siyao Pharmaceuticals Co., Ltd.
5 Prospect of China’s Metoprolol Market, 2018-2022
5.1 Forecast on Market Size
5.2 Forecast on Market Trend
Selected Charts
Chart Sales of Metoprolol in China, 2013-2017
Chart Sales Value of Metoprolol in Parts of China, 2013-2017
Chart Sales Volume of Metoprolol in China, 2013-2017
Chart Sales Volume of Metoprolol in Parts of China, 2013-2017
Chart Sales Value of Metoprolol Injections in China, 2013-2017
Chart Sales Volume of Metoprolol Injections in China, 2013-2017
Chart Sales Value of Metoprolol Tablets in China, 2013-2017
Chart Sales Volume of Metoprolol Tablets in China, 2013-2017
Chart Market Share of Top 5 Metoprolol Manufacturers by Sales Value, 2013-2017
Chart Market Share of Top 5 Metoprolol Manufacturers by Sales Volume, 2013-2017
Chart Sales Value of AstraZeneca’s Metoprolol, 2013-2017
Chart Sales Volume of AstraZeneca’s Metoprolol, 2013-2017
Chart Sales Value of Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd.’s Metoprolol, 2013-2017
Chart Sales Volume of Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd.’s Metoprolol, 2013-2017
Chart Sales Value of Shanghai Sine Promod Pharmaceutical Co., Ltd.’s Metoprolol, 2013-2017
Chart Sales Volume of Shanghai Sine Promod Pharmaceutical Co., Ltd.’s Metoprolol, 2013-2017
Chart Sales Value of Zhuhai Tongyuan Pharmaceutical Co., Ltd.’s Metoprolol, 2013-2017
Chart Sales Volume of Zhuhai Tongyuan Pharmaceutical Co., Ltd.’s Metoprolol, 2013-2017
Chart Sales Value of Changzhou Siyao Pharmaceuticals Co., Ltd.’s Metoprolol, 2013-2017
Chart Prices of AstraZeneca’s Metoprolol in Parts of China, 2017-2018
Chart Prices of Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd.’s Metoprolol in Parts of China, 2017-2018
Chart Prices of Shanghai Sine Promod Pharmaceutical Co., Ltd.’s Metoprolol in Parts of China, 2017-2018
Chart Prices of Zhuhai Tongyuan Pharmaceutical Co., Ltd.’s Metoprolol in Parts of China, 2017-2018
Chart Prices of Changzhou Siyao Pharmaceuticals Co., Ltd.’s Metoprolol in Parts of China, 2017-2018
Chart Forecast on Sales Value of Metoprolol in China, 2018-2022
